A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.

A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.

BACKGROUND: There is little consensus on a standard approach to analysing bone scan images. The Bone Scan Index (BSI) is predictive of survival in patients with progressive prostate cancer (PCa), but the popularity of this metric is hampered by the tedium of the manual calculation. OBJECTIVE: Develo...

Bibliografski detalji
Glavni autori:	Ulmert, D, Kaboteh, R, Fox, J, Savage, C, Evans, M, Lilja, H, Abrahamsson, P, Björk, T, Gerdtsson, A, Bjartell, A, Gjertsson, P, Höglund, P, Lomsky, M, Ohlsson, M, Richter, J, Sadik, M, Morris, M, Scher, H, Sjöstrand, K, Yu, A, Suurküla, M, Edenbrandt, L, Larson, S
Format:	Journal article
Jezik:	English
Izdano:	2012

Slični predmeti

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
od: Ulmert, D, i dr.
Izdano: (2009)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
od: Vickers, A, i dr.
Izdano: (2010)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study
od: Vickers, A, i dr.
Izdano: (2010)

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
od: Lilja, H, i dr.
Izdano: (2007)

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
od: Vickers, A, i dr.
Izdano: (2011)

Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.
od: Ulmert, D, i dr.
Izdano: (2012)

Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
od: Klein, R, i dr.
Izdano: (2012)

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
od: Savage, C, i dr.
Izdano: (2010)

A prospective study to evaluate the intra-individual reproducibility of bone scans for quantitative assessment in patients with metastatic prostate cancer
od: Mariana Reza, i dr.
Izdano: (2018-05-01)

Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation.
od: Bruun, L, i dr.
Izdano: (2004)

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.
od: Vickers, A, i dr.
Izdano: (2007)

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
od: Lilja, H, i dr.
Izdano: (2011)

Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.
od: Ulmert, D, i dr.
Izdano: (2012)

Editorial Comment
od: Ulmert, D, i dr.
Izdano: (2008)

miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions.
od: Hagman, Z, i dr.
Izdano: (2010)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
od: Lilja, H, i dr.
Izdano: (2008)

Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring (Corrigendum) (Nature Reviews Cancer (2008) 8, (268-278))
od: Lilja, H, i dr.
Izdano: (2008)

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.
od: Ulmert, D, i dr.
Izdano: (2008)

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
od: Ulmert, D, i dr.
Izdano: (2008)

Tumor markers in prostate cancer I: blood-based markers.
od: Shariat, S, i dr.
Izdano: (2011)

A simple statistical model for prediction of acute coronary syndrome in chest pain patients in the emergency department
od: Edenbrandt Lars, i dr.
Izdano: (2006-07-01)

Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C.
od: Ulmert, D, i dr.
Izdano: (2006)

Small average differences in attenuation corrected images between men and women in myocardial perfusion scintigraphy: a novel normal stress database
od: Jakobsson David, i dr.
Izdano: (2011-10-01)

3D skeletal uptake of 18F sodium fluoride in PET/CT images is associated with overall survival in patients with prostate cancer
od: Sarah Lindgren Belal, i dr.
Izdano: (2017-02-01)

Correction to: 3D skeletal uptake of 18F sodium fluoride in PET/CT images is associated with overall survival in patients with prostate cancer
od: Sarah Lindgren Belal, i dr.
Izdano: (2019-05-01)

Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland.
od: Bjartell, A, i dr.
Izdano: (2006)

Detection of androgen receptor mutations in circulating tumor cells: highlights of the long road to clinical qualification.
od: Lilja, H, i dr.
Izdano: (2010)

Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections.
od: Siivola, P, i dr.
Izdano: (2000)

Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues.
od: Olsson, A, i dr.
Izdano: (2005)

Time-resolved fluorescence imaging for quantitative histochemistry using lanthanide chelates in nanoparticles and conjugated to monoclonal antibodies.
od: Väisänen, V, i dr.
Izdano: (2000)

RECOMIA—a cloud-based platform for artificial intelligence research in nuclear medicine and radiology
od: Elin Trägårdh, i dr.
Izdano: (2020-08-01)

AI-based detection of lung lesions in [18F]FDG PET-CT from lung cancer patients
od: Pablo Borrelli, i dr.
Izdano: (2021-03-01)

Artificial intelligence-aided CT segmentation for body composition analysis: a validation study
od: Pablo Borrelli, i dr.
Izdano: (2021-03-01)

Analgesic and Nonanalgesic Effects of Intravenous Hydromorphone - Relation to Plasma Concentrations in Healthy Volunteers
od: D Westerling, i dr.
Izdano: (1996-01-01)

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
od: Christensson, A, i dr.
Izdano: (2011)

Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.
od: Evans-Axelsson, S, i dr.
Izdano: (2012)

α2-macroglobulin and α1-inhibitor-3 mRNA expression in the rat liver after slow interleukin-1 stimulation
od: T. Gudmundsson, i dr.
Izdano: (1996-01-01)

A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue.
od: Valtonen-André, C, i dr.
Izdano: (2007)

Expression and immunolocalisation of neutral endopeptidase in prostate cancer.
od: Albrecht, M, i dr.
Izdano: (2003)

AI-based fully automatic image analysis: Optimal abdominal and thoracic segmentation volumes for estimating total muscle volume on computed tomography scans
od: Thomas Ying, i dr.
Izdano: (2024-06-01)